Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have earned a consensus recommendation of "Buy" from the nine brokerages that are currently covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $54.33.

Several research firms have commented on DNTH. Raymond James upgraded shares of Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Wedbush reiterated an "outperform" rating and set a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim reissued a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. TD Cowen started coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a "buy" rating for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th.

Dianthus Therapeutics Trading Down 4.5 %

Dianthus Therapeutics stock traded down $0.73 during trading on Friday, hitting $15.60. 876,597 shares of the company were exchanged, compared to its average volume of 258,935. The company has a market capitalization of $501.15 million, a P/E ratio of -6.24 and a beta of 1.62. The business's 50 day moving average is $20.76 and its 200 day moving average is $23.45. Dianthus Therapeutics has a 52 week low of $13.37 and a 52 week high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Equities analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DNTH. MetLife Investment Management LLC lifted its stake in shares of Dianthus Therapeutics by 3.1% during the 4th quarter. MetLife Investment Management LLC now owns 14,372 shares of the company's stock valued at $313,000 after buying an additional 433 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Dianthus Therapeutics by 7.4% in the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company's stock worth $251,000 after acquiring an additional 790 shares during the period. SG Americas Securities LLC raised its stake in shares of Dianthus Therapeutics by 9.2% during the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company's stock valued at $210,000 after purchasing an additional 814 shares during the period. Barclays PLC lifted its holdings in Dianthus Therapeutics by 2.6% during the 4th quarter. Barclays PLC now owns 42,766 shares of the company's stock worth $933,000 after purchasing an additional 1,082 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Dianthus Therapeutics by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company's stock worth $3,641,000 after purchasing an additional 1,092 shares during the period. Institutional investors own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.